Innovate Rheumatology
Smart, Digitalized, Personalized and Precise
Rheumatology is at the edge of transformation. How can the entire therapy journey from prevention via identification and diagnosis to treatment be individualized and optimized with the help of modern technologies? Unleash your creativity, use your imagination to tackle this plethora of challenging issues and make an impact on one of the most prevalent diseases in society.
Optional: In our free and optional Design Thinking Workshop we will help you to innovate your idea and will connect you with other participants - Register here.
✅ Challenge completed 🏁 Winner Congratulations to Vila Health, ScientaLab and Midaia for winning the Challenge. Special rewards for their innovative ideas were also given to "Cynteract" and "Joint-on-Chip"🏆 Rewards 8.000€ prize pool + working together with experts from rheumatology + possibility of further cooperation with medac
Who are we?
medac stands for ...
... a human point of view.
We are a privately held, medium-sized global pharmaceutical and diagnostics company based in Germany. For more than 50 years we have been committed to high‑quality products, reliable supply and individual customer services. Today, over 1,900 medac employees worldwide are working together to supply more than 90 countries with our products.
Our vision is to improve patients’ quality of life with high‑quality therapies that are affordable and always available. This dedication is reflected in our comprehensive portfolio.
Since our foundation we have been specialising in the treatment of oncological, haematological, urological, and autoimmune diseases. Today, we are a leading specialist supplier in oncology and rheumatology.
We combine the innovative power of a researching pharmaceutical company with the efficiency of a generics manufacturer and offer both therapeutics and diagnostics.
Always putting the needs of patients and healthcare professionals first, we are committed to the refinement of established and the development of new products with additional benefits for patients in specific niche indications with high therapeutic needs. Despite being a medium‑sized company and smaller profit margins, our purpose is nevertheless to make therapies for rare diseases available.
Knowing that digital products will be a key success factor for us in the future we are also striving to become an expert in new technologies and intensify our innovation efforts. This is why we are initiating the Innovate Rheumatology Challenge with ekipa
© 2018- 2025 ekipa GmbH. All rights reserved.